chemotherapy: R-CHOP

PROCEDURE2 trials

Sponsors

European Mantle Cell Lymphoma Network

Conditions

Lymphoma, Mantle-Cell

Phase 3

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

European Mantle Cell Lymphoma NetworkLymphoma, Mantle-Cell

Start: 2004-07-31End: 2014-12-31Target: 360Updated: 2012-09-10

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

European Mantle Cell Lymphoma NetworkLymphoma, Mantle-Cell

Start: 2004-01-14End: 2018-12-31Target: 570Updated: 2017-03-07

Related Papers

Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

Blood2024-11-05

<i>Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care?</i>

Blood2024-11-05

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood2023-11-029 citations

A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial

Cancers2021-12-3113 citations

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial

Journal of Clinical Oncology2019-12-05134 citations

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

2016-06-14280 citations

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Blood2015-05-29154 citations

Treatment of older patients with mantle-cell lymphoma.

2012-08-01351 citations

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

2009-12-23207 citations